Anika Therapeutics Inc Net Assets
Anika Therapeutics Inc net assets. Based on the latest financial reports, Anika Therapeutics Inc (ANIK) has net assets worth $137.28 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($183.47 Million) and total liabilities ($46.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Anika Therapeutics Inc annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $137.28 Million |
| % of Total Assets | 74.82% |
| Annual Growth Rate | 10.05% |
| 5-Year Change | -50.03% |
| 10-Year Change | -35.6% |
| Growth Volatility | 75.26 |
Net Assets of Anika Therapeutics Inc (1993–2025)
Net assets of Anika Therapeutics Inc from 1993 to 2025. This chart illustrates how Anika Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See ANIK equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Anika Therapeutics Inc (1993–2025)
The table below shows the annual net assets of Anika Therapeutics Inc from 1993 to 2025. For live market cap and overall valuation, see how much is Anika Therapeutics Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $143.47 Million | -6.83% |
| 2024-12-31 | $153.99 Million | -27.45% |
| 2023-12-31 | $212.26 Million | -25.67% |
| 2022-12-31 | $285.56 Million | -0.53% |
| 2021-12-31 | $287.08 Million | +5.39% |
| 2020-12-31 | $272.40 Million | -5.54% |
| 2019-12-31 | $288.38 Million | +9.39% |
| 2018-12-31 | $263.61 Million | +0.05% |
| 2017-12-31 | $263.49 Million | +18.28% |
| 2016-12-31 | $222.77 Million | +5.66% |
| 2015-12-31 | $210.85 Million | +18.39% |
| 2014-12-31 | $178.10 Million | +31.31% |
| 2013-12-31 | $135.63 Million | +24.52% |
| 2012-12-31 | $108.93 Million | +14.95% |
| 2011-12-31 | $94.76 Million | +11.24% |
| 2010-12-31 | $85.19 Million | +3.71% |
| 2009-12-31 | $82.14 Million | +35.20% |
| 2008-12-31 | $60.76 Million | +10.55% |
| 2007-12-31 | $54.96 Million | +20.83% |
| 2006-12-31 | $45.49 Million | +20.05% |
| 2005-12-31 | $37.89 Million | +24.80% |
| 2004-12-31 | $30.36 Million | +68.83% |
| 2003-12-31 | $17.98 Million | +5.39% |
| 2002-12-31 | $17.06 Million | -15.12% |
| 2001-12-31 | $20.10 Million | -24.74% |
| 2000-12-31 | $26.71 Million | +3.94% |
| 1999-12-31 | $25.70 Million | -14.05% |
| 1998-12-31 | $29.90 Million | +14.12% |
| 1997-12-31 | $26.20 Million | +424.00% |
| 1996-12-31 | $5.00 Million | -13.79% |
| 1995-12-31 | $5.80 Million | +7.41% |
| 1994-12-31 | $5.40 Million | -19.40% |
| 1993-12-31 | $6.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Anika Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6128700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Anika Therapeutics Inc Net Assets Breakdown (December 2025)
Anika Therapeutics Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $60.79 Million | 42.37% |
| Common Stock | $139.00K | 0.10% |
| Other Comprehensive Income | $-4.96 Million | -3.46% |
| Other Components | $87.50 Million | 60.99% |
| Total Equity | $143.47 Million | 100.00% |
Anika Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Anika Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DYNAM JAPAN HOLDINGS Co. Ltd
F:2DJ
|
$260.37 Million |
|
Columbus Circle Capital Corp I Class A Ordinary Shares
NASDAQ:CCCM
|
$260.39 Million |
|
Mahamaya Steel Industries Limited
NSE:MAHASTEEL
|
$260.41 Million |
|
Daedalus Special Acquisition Corp.
NASDAQ:DSAC
|
$260.45 Million |
|
Il Dong Pharmaceutical Co Ltd
KO:249420
|
$260.29 Million |
|
Zhejiang Dilong New Material Co Ltd
SHE:002247
|
$260.22 Million |
|
Beijing Piesat Information Technology Co Ltd
SHG:688066
|
$259.99 Million |
|
Karmarts Public Company Limited
BK:KAMART
|
$259.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Anika Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 153,989,000 to 143,465,000, a change of -10,524,000 (-6.8%).
- Net loss of 10,880,000 reduced equity.
- Share repurchases of 9,485,000 reduced equity.
- Other comprehensive income increased equity by 1,824,000.
- Other factors increased equity by 8,017,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.88 Million | -7.58% |
| Share Repurchases | $9.48 Million | -6.61% |
| Other Comprehensive Income | $1.82 Million | +1.27% |
| Other Changes | $8.02 Million | +5.59% |
| Total Change | $- | -6.83% |
Book Value vs Market Value Analysis
This analysis compares Anika Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.94x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 9.11x to 1.94x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1993-12-31 | $2.14 | $19.45 | x |
| 1994-12-31 | $1.74 | $19.45 | x |
| 1995-12-31 | $1.77 | $19.45 | x |
| 1996-12-31 | $1.04 | $19.45 | x |
| 1997-12-31 | $3.49 | $19.45 | x |
| 1998-12-31 | $2.72 | $19.45 | x |
| 1999-12-31 | $2.51 | $19.45 | x |
| 2000-12-31 | $2.66 | $19.45 | x |
| 2001-12-31 | $2.02 | $19.45 | x |
| 2002-12-31 | $1.72 | $19.45 | x |
| 2003-12-31 | $1.66 | $19.45 | x |
| 2004-12-31 | $2.66 | $19.45 | x |
| 2005-12-31 | $3.32 | $19.45 | x |
| 2006-12-31 | $4.08 | $19.45 | x |
| 2007-12-31 | $4.80 | $19.45 | x |
| 2008-12-31 | $5.30 | $19.45 | x |
| 2009-12-31 | $7.10 | $19.45 | x |
| 2010-12-31 | $6.24 | $19.45 | x |
| 2011-12-31 | $6.89 | $19.45 | x |
| 2012-12-31 | $7.59 | $19.45 | x |
| 2013-12-31 | $9.15 | $19.45 | x |
| 2014-12-31 | $11.66 | $19.45 | x |
| 2015-12-31 | $13.76 | $19.45 | x |
| 2016-12-31 | $14.74 | $19.45 | x |
| 2017-12-31 | $17.49 | $19.45 | x |
| 2018-12-31 | $17.95 | $19.45 | x |
| 2019-12-31 | $20.06 | $19.45 | x |
| 2020-12-31 | $19.15 | $19.45 | x |
| 2021-12-31 | $19.62 | $19.45 | x |
| 2022-12-31 | $19.61 | $19.45 | x |
| 2023-12-31 | $14.48 | $19.45 | x |
| 2024-12-31 | $10.46 | $19.45 | x |
| 2025-12-31 | $10.01 | $19.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Anika Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.58%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -9.64%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 1.33x
- Recent ROE (-7.58%) is below the historical average (-1.81%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1993 | -23.88% | -72.73% | 0.23x | 1.43x | $-2.27 Million |
| 1994 | -25.93% | -29.79% | 0.61x | 1.43x | $-1.94 Million |
| 1995 | -34.48% | -58.82% | 0.43x | 1.38x | $-2.58 Million |
| 1996 | -54.00% | -225.00% | 0.17x | 1.38x | $-3.20 Million |
| 1997 | 12.60% | 27.50% | 0.42x | 1.10x | $680.00K |
| 1998 | 14.38% | 30.94% | 0.43x | 1.08x | $1.31 Million |
| 1999 | -9.73% | -18.52% | 0.42x | 1.26x | $-5.07 Million |
| 2000 | 0.65% | 1.06% | 0.56x | 1.08x | $-2.50 Million |
| 2001 | -33.61% | -59.74% | 0.49x | 1.14x | $-8.77 Million |
| 2002 | -17.82% | -23.05% | 0.66x | 1.18x | $-4.75 Million |
| 2003 | 4.60% | 5.37% | 0.70x | 1.22x | $-971.40K |
| 2004 | 36.85% | 42.28% | 0.44x | 1.96x | $8.15 Million |
| 2005 | 15.55% | 19.75% | 0.48x | 1.65x | $2.10 Million |
| 2006 | 10.12% | 17.15% | 0.39x | 1.50x | $55.41K |
| 2007 | 10.98% | 19.58% | 0.39x | 1.45x | $539.16K |
| 2008 | 5.97% | 10.14% | 0.37x | 1.58x | $-2.45 Million |
| 2009 | 4.49% | 9.19% | 0.31x | 1.59x | $-4.53 Million |
| 2010 | 5.07% | 7.77% | 0.43x | 1.51x | $-4.20 Million |
| 2011 | 8.93% | 13.07% | 0.49x | 1.40x | $-1.01 Million |
| 2012 | 10.79% | 16.48% | 0.50x | 1.30x | $864.95K |
| 2013 | 15.17% | 27.40% | 0.48x | 1.15x | $7.01 Million |
| 2014 | 21.52% | 36.29% | 0.54x | 1.09x | $20.51 Million |
| 2015 | 14.59% | 33.07% | 0.39x | 1.12x | $9.67 Million |
| 2016 | 14.61% | 31.48% | 0.43x | 1.08x | $10.27 Million |
| 2017 | 12.07% | 28.05% | 0.40x | 1.07x | $5.47 Million |
| 2018 | 7.10% | 17.74% | 0.38x | 1.06x | $-7.64 Million |
| 2019 | 9.43% | 23.73% | 0.35x | 1.15x | $-1.64 Million |
| 2020 | -8.80% | -18.38% | 0.36x | 1.34x | $-51.22 Million |
| 2021 | 1.44% | 2.80% | 0.43x | 1.21x | $-24.57 Million |
| 2022 | -5.20% | -9.51% | 0.45x | 1.22x | $-43.42 Million |
| 2023 | -38.95% | -68.44% | 0.45x | 1.27x | $-103.89 Million |
| 2024 | -36.62% | -47.02% | 0.59x | 1.32x | $-71.78 Million |
| 2025 | -7.58% | -9.64% | 0.59x | 1.33x | $-25.23 Million |
Industry Comparison
This section compares Anika Therapeutics Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $81,278,137
- Average return on equity (ROE) among peers: 28.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Anika Therapeutics Inc (ANIK) | $137.28 Million | -23.88% | 0.34x | $260.30 Million |
| Aurora Cannabis Inc (ACB) | $1.71 Million | -2.57% | 0.01x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $335.50 Million | -73.41% | 0.53x | $143.73 Million |
| Akanda Corp (AKAN) | $4.28 Million | -95.78% | 0.85x | $584.11K |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $194.43 Million |
| Alkermes Plc (ALKS) | $18.84 Million | -398.98% | 9.71x | $7.67 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-151.17 Million | 0.00% | 0.00x | $3.25 Billion |
| Amphastar P (AMPH) | $233.44 Million | 7.75% | 0.36x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $5.96 Million | 1208.40% | 615.85x | $5.92 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $208.93 Million | -62.22% | 17.18x | $3.57 Billion |
About Anika Therapeutics Inc
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-op… Read more